Literature DB >> 21911634

Prospective evaluation of analgesic use and risk of renal cell cancer.

Eunyoung Cho1, Gary Curhan, Susan E Hankinson, Philip Kantoff, Michael B Atkins, Meir Stampfer, Toni K Choueiri.   

Abstract

BACKGROUND: Epidemiologic data suggest that analgesic use increases the risk of renal cell cancer (RCC), but few prospective studies have been published. We investigated the association between analgesic use and RCC in 2 large prospective studies.
METHODS: We examined the relationship between analgesic use and RCC risk in the Nurses' Health Study and the Health Professionals Follow-up Study. Use of aspirin, other nonsteroidal anti-inflammatory drugs (NSAIDs), and acetaminophen was ascertained in 1990 in the Nurses' Health Study and in 1986 in the Health Professionals Follow-up Study, and every 2 years thereafter. We evaluated baseline and duration of use of analgesics.
RESULTS: During follow-up of 16 years among 77,525 women and 20 years among 49,403 men, we documented 333 RCC cases. Aspirin and acetaminophen use were not associated with RCC risk. However, regular use of nonaspirin NSAIDs was associated with an increased RCC risk; the pooled multivariate relative risk was 1.51 (95% confidence interval, 1.12-2.04) at baseline. The absolute risk differences for users vs nonusers of nonaspirin NSAIDs were 9.15 per 100 000 person-years in women and 10.92 per 100,000 person-years in men. There was a dose-response relationship between duration of nonaspirin NSAID use and RCC risk; compared with nonregular use, the pooled multivariate relative risks were 0.81 (95% confidence interval, 0.59-1.11) for use less than 4 years, 1.36 (0.98-1.89) for 4 to less than 10 years, and 2.92 (1.71-5.01) for use for 10 or more years (P < .001 for trend).
CONCLUSION: Our prospective data suggest that longer duration of use of nonaspirin NSAIDs may increase the risk of RCC.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21911634      PMCID: PMC3691864          DOI: 10.1001/archinternmed.2011.356

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  37 in total

1.  Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials.

Authors:  Jeffrey S Berger; Maria C Roncaglioni; Fausto Avanzini; Ierta Pangrazzi; Gianni Tognoni; David L Brown
Journal:  JAMA       Date:  2006-01-18       Impact factor: 56.272

2.  Meta-analysis in clinical trials.

Authors:  R DerSimonian; N Laird
Journal:  Control Clin Trials       Date:  1986-09

3.  The analysis of failure times in the presence of competing risks.

Authors:  R L Prentice; J D Kalbfleisch; A V Peterson; N Flournoy; V T Farewell; N E Breslow
Journal:  Biometrics       Date:  1978-12       Impact factor: 2.571

Review 4.  Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force.

Authors:  Alaa Rostom; Catherine Dubé; Gabriela Lewin; Alexander Tsertsvadze; Nicholas Barrowman; Catherine Code; Margaret Sampson; David Moher
Journal:  Ann Intern Med       Date:  2007-03-06       Impact factor: 25.391

Review 5.  Aspirin and cancer risk: an updated quantitative review to 2005.

Authors:  Cristina Bosetti; Silvano Gallus; Carlo La Vecchia
Journal:  Cancer Causes Control       Date:  2006-09       Impact factor: 2.506

6.  Nonsteroidal antiinflammatory drugs, acetaminophen, and the risk of cardiovascular events.

Authors:  Andrew T Chan; JoAnn E Manson; Christine M Albert; Claudia U Chae; Kathryn M Rexrode; Gary C Curhan; Eric B Rimm; Walter C Willett; Charles S Fuchs
Journal:  Circulation       Date:  2006-03-13       Impact factor: 29.690

7.  Lifetime nonnarcotic analgesic use and decline in renal function in women.

Authors:  Gary C Curhan; Eric L Knight; Bernard Rosner; Susan E Hankinson; Meir J Stampfer
Journal:  Arch Intern Med       Date:  2004-07-26

8.  Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States.

Authors:  Dima M Qato; G Caleb Alexander; Rena M Conti; Michael Johnson; Phil Schumm; Stacy Tessler Lindau
Journal:  JAMA       Date:  2008-12-24       Impact factor: 56.272

9.  Nonsteroidal anti-inflammatory drugs and prostate cancer: a systematic review of the literature and meta-analysis.

Authors:  Siavash Jafari; Mahyar Etminan; Kourosh Afshar
Journal:  Can Urol Assoc J       Date:  2009-08       Impact factor: 1.862

10.  Risk of cancer in a large cohort of nonaspirin NSAID users: a population-based study.

Authors:  H T Sørensen; S Friis; B Nørgård; L Mellemkjaer; W J Blot; J K McLaughlin; A Ekbom; J A Baron
Journal:  Br J Cancer       Date:  2003-06-02       Impact factor: 7.640

View more
  24 in total

1.  Kidney cancer: long-term use of nonaspirin NSAIDs increases RCC risk.

Authors:  Annette Fenner
Journal:  Nat Rev Urol       Date:  2011-10-04       Impact factor: 14.432

Review 2.  Aspirin and urologic cancer risk: an update.

Authors:  Cristina Bosetti; Valentina Rosato; Silvano Gallus; Carlo La Vecchia
Journal:  Nat Rev Urol       Date:  2012-01-24       Impact factor: 14.432

3.  Trends in Renal-Cell Carcinoma Incidence and Mortality in the United States in the Last 2 Decades: A SEER-Based Study.

Authors:  Anas M Saad; Mohamed M Gad; Muneer J Al-Husseini; Inas A Ruhban; Mohamad Bassam Sonbol; Thai H Ho
Journal:  Clin Genitourin Cancer       Date:  2018-10-11       Impact factor: 2.872

4.  Metastatic Renal Cell Carcinoma Presenting as Painful Chewing Successfully Treated with Combined Nivolumab and Sunitinib.

Authors:  Fade Mahmoud; Al-Ola Abdallah; Konstantinos Arnaoutakis; Issam Makhoul
Journal:  Perm J       Date:  2016-06-27

5.  The Global Burden of Cancer 2013.

Authors:  Christina Fitzmaurice; Daniel Dicker; Amanda Pain; Hannah Hamavid; Maziar Moradi-Lakeh; Michael F MacIntyre; Christine Allen; Gillian Hansen; Rachel Woodbrook; Charles Wolfe; Randah R Hamadeh; Ami Moore; Andrea Werdecker; Bradford D Gessner; Braden Te Ao; Brian McMahon; Chante Karimkhani; Chuanhua Yu; Graham S Cooke; David C Schwebel; David O Carpenter; David M Pereira; Denis Nash; Dhruv S Kazi; Diego De Leo; Dietrich Plass; Kingsley N Ukwaja; George D Thurston; Kim Yun Jin; Edgar P Simard; Edward Mills; Eun-Kee Park; Ferrán Catalá-López; Gabrielle deVeber; Carolyn Gotay; Gulfaraz Khan; H Dean Hosgood; Itamar S Santos; Janet L Leasher; Jasvinder Singh; James Leigh; Jost B Jonas; Jost Jonas; Juan Sanabria; Justin Beardsley; Kathryn H Jacobsen; Ken Takahashi; Richard C Franklin; Luca Ronfani; Marcella Montico; Luigi Naldi; Marcello Tonelli; Johanna Geleijnse; Max Petzold; Mark G Shrime; Mustafa Younis; Naohiro Yonemoto; Nicholas Breitborde; Paul Yip; Farshad Pourmalek; Paulo A Lotufo; Alireza Esteghamati; Graeme J Hankey; Raghib Ali; Raimundas Lunevicius; Reza Malekzadeh; Robert Dellavalle; Robert Weintraub; Robyn Lucas; Roderick Hay; David Rojas-Rueda; Ronny Westerman; Sadaf G Sepanlou; Sandra Nolte; Scott Patten; Scott Weichenthal; Semaw Ferede Abera; Seyed-Mohammad Fereshtehnejad; Ivy Shiue; Tim Driscoll; Tommi Vasankari; Ubai Alsharif; Vafa Rahimi-Movaghar; Vasiliy V Vlassov; W S Marcenes; Wubegzier Mekonnen; Yohannes Adama Melaku; Yuichiro Yano; Al Artaman; Ismael Campos; Jennifer MacLachlan; Ulrich Mueller; Daniel Kim; Matias Trillini; Babak Eshrati; Hywel C Williams; Kenji Shibuya; Rakhi Dandona; Kinnari Murthy; Benjamin Cowie; Azmeraw T Amare; Carl Abelardo Antonio; Carlos Castañeda-Orjuela; Coen H van Gool; Francesco Violante; In-Hwan Oh; Kedede Deribe; Kjetil Soreide; Luke Knibbs; Maia Kereselidze; Mark Green; Rosario Cardenas; Nobhojit Roy; Taavi Tillmann; Taavi Tillman; Yongmei Li; Hans Krueger; Lorenzo Monasta; Subhojit Dey; Sara Sheikhbahaei; Nima Hafezi-Nejad; G Anil Kumar; Chandrashekhar T Sreeramareddy; Lalit Dandona; Haidong Wang; Stein Emil Vollset; Ali Mokdad; Joshua A Salomon; Rafael Lozano; Theo Vos; Mohammad Forouzanfar; Alan Lopez; Christopher Murray; Mohsen Naghavi
Journal:  JAMA Oncol       Date:  2015-07       Impact factor: 31.777

6.  Non-steroidal anti-inflammatory drugs and amyotrophic lateral sclerosis: results from five prospective cohort studies.

Authors:  Elinor Fondell; Éilis J O'Reilly; Kathryn C Fitzgerald; Guido J Falcone; Marjorie L McCullough; Michael J Thun; Yikyung Park; Laurence N Kolonel; Alberto Ascherio
Journal:  Amyotroph Lateral Scler       Date:  2012-08-07

7.  Duration of Analgesic Use and Risk of Hearing Loss in Women.

Authors:  Brian M Lin; Sharon G Curhan; Molin Wang; Roland Eavey; Konstantina M Stankovic; Gary C Curhan
Journal:  Am J Epidemiol       Date:  2016-12-14       Impact factor: 4.897

8.  Analgesic use and the risk of hearing loss in women.

Authors:  Sharon G Curhan; Josef Shargorodsky; Roland Eavey; Gary C Curhan
Journal:  Am J Epidemiol       Date:  2012-08-29       Impact factor: 4.897

9.  A large cohort study of nonsteroidal anti-inflammatory drugs and renal cell carcinoma incidence in the National Institutes of Health-AARP Diet and Health Study.

Authors:  Wei Liu; Yikyung Park; Mark P Purdue; Edward Giovannucci; Eunyoung Cho
Journal:  Cancer Causes Control       Date:  2013-07-19       Impact factor: 2.506

10.  Dietary Acrylamide Intake and Risk of Renal Cell Carcinoma in Two Large Prospective Cohorts.

Authors:  Rebecca E Graff; Eunyoung Cho; Mark A Preston; Alejandro Sanchez; Lorelei A Mucci; Kathryn M Wilson
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2018-05-14       Impact factor: 4.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.